Work

Clinical features and prognosis analysis of non-HIV Pneumocystis jirovecii pneumonia: a multi-center retrospective cohort study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective The rising global incidence of Pneumocystis jirovecii pneumonia (PJP) in HIV-negative populations, characterized by atypical presentation, rapid progression, and high mortality, poses a significant clinical challenge. This study aimed to summarize the clinical, diagnostic, and therapeutic profiles of HIV-negative PJP and identify independent prognostic factors to refine clinical management. Methods A retrospective multicenter analysis was conducted on 233 HIV-negative PJP patients from five tertiary hospitals (December 2019 – June 2025), stratified into survivors ( n = 135) and non-survivors ( n = 98). Baseline demographics, laboratory indices, imaging, diagnostic modalities, and treatments were compared. Univariate and multivariate logistic regression identified mortality risk factors. Results The cohort (167 males, 66 females; mean age 53.00 ± 18.25 years) had a median symptom-to-admission time of 5 days and median hospital stay of 18 days. Underlying diseases were present in 84.55%. Atypical symptoms were common; 66.09% had an oxygenation index <300 mmHg (median 217.03; IQR 109.72–325.70), and 28.33% were 1,3- β -D-glucan positive. Significant intergroup differences ( P < 0.05) were observed for several laboratory and physiological parameters, including platelet count (PLT), procalcitonin (PCT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), oxygenation index (OI), 1,3- β -D-glucan (BDG), and tachypnea (≥30/min). Imaging revealed ground-glass opacities, patchy shadows, and septal thickening; pleural effusion, consolidation, and nodules differed significantly between groups ( P < 0.05). Among 197 mNGS-tested patients, polymicrobial co-detection was common, with viral, bacterial, and fungal positivity rates of 69.04%, 38.07%, and 26.40%, respectively; EBV, H. parainfluenzae , and P. aeruginosa were more frequently co-detected in non-survivors ( P < 0.05). Treatments, including antivirals, immunoglobulins, and mechanical ventilation, differed significantly ( P < 0.05). Multivariate analysis identified smoking history (OR = 1.818, 95% CI: 1.043–3.170, P = 0.035), shock (OR = 2.787, 95% CI: 1.453–5.348, P = 0.002), underlying pulmonary disease (OR = 3.488, 95% CI: 1.864–6.524, P < 0.001), positive BALF EBV nucleic acid (OR = 6.635, 95% CI: 1.281–34.362, P = 0.024), AST (OR = 1.033, 95% CI: 1.025–1.042, P < 0.001), and tachypnea ≥30/min (OR = 2.520, 95% CI: 1.286–4.938, P = 0.007) as independent mortality risk factors. The multivariable model achieved an AUC of 0.857 from ROC analysis. Conclusion HIV-negative PJP presents with nonspecific features and frequent polymicrobial co-detection of pathogens, contributing to high 28-day all-cause mortality. BALF mNGS can simultaneously detect Pneumocystis jirovecii and polymicrobial co-pathogens in immunocompromised patients, yet this retrospective cohort was not designed as a diagnostic accuracy trial; mNGS can only act as an auxiliary pathogen detection tool rather than a universal early screening test for suspected PJP. Close monitoring of these identified exploratory risk factors and timely targeted interventions are crucial for improving prognosis. Further external-cohort validations are warranted before applying these markers for clinical risk stratification.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235449128
FWCI:
Cites: 42
Cited by:
Related to: 10
Parts: 1